Retina Consultants of Hawaii Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2010
NCT01248117
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Alternative names

Retina Consultants of Hawaii, Pali Momi Medical Center

Active Ingredients

Drugs in Phase 2 Trials (2)

ico-007 (1 trial)

ranibizumab (lucentis) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Edema (Phase 2)

Macular Edema (Phase 2)

Vascular Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2